Table 2 Summary of multivariable assessments for progression-free-survival.

From: Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience

Parameter

Hazard Ratio (95% CI)

p-value

ISS

II vs I

1.47 (0.91, 2.36)

0.12

III vs I

0.91 (0.51, 1.63)

0.76

Unknown vs I

1.13 (0.54, 2.36)

0.75

Prior MRD/Response

Negative/≥VGPR vs Other

0.52 (0.31, 0.87)

0.013

Number of additional copies of 1q + 

> 1 vs 1

2.03 (1.27, 3.22)

0.003

t(4;14)

Present vs Absent

1.61 (0.77, 3.36)

0.20

Not done vs Absent

1.86 (0.93, 3.74)

0.08

t(14;16)

Present vs Absent

2.26 (0.86, 5.91)

0.10

Not done vs Absent

0.69 (0.32, 1.52)

0.36

100-day MRD/responsea

Negative/≥VGPR vs Other

0.71 (0.46, 1.09)

0.12

Maintenance therapya

Lenalidomide vs Other

0.68 (0.45, 1.03)

0.07

  1. CI Confidence interval, ISS International Staging System, MRD Minimal residual disease, ref reference group, VGPR very good partial response.
  2. aIncluded in the model as a time-dependent covariate.
Back to article page